TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37437575
Drug: Intensive and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive and personalized-dosage cumulative intervention combining brain-computer interface, exoskeleton, multi-channel functional electrical stimulation, and anodal transcranial direct current stimulation
Study: 37437608
Drug: High-dose intensity-modulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intensity-modulated radiotherapy (RT) with pre-operative helical tomotherapy, delivering 54 Gy/30 fractions
Study: 37437694
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment (antihypertensive medications with goal blood pressure <140/90 mm Hg)
Study: 37437694
Drug: Control (deferred
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (deferred treatment until blood pressure ≥160/105 mm Hg)
Study: 37437885
Drug: Vilaprisan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vilaprisan (2 mg/d)
Study: 37438197
Drug: ivacaftor therapy
Normalized name: Ivacaftor
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: ivacaftor therapy
Study: 37438493
Drug: Oral prolonged-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prolonged-release tablet (1.9 mg melatonin)
Study: 37438493
Drug: Immediate-release sublingual
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release sublingual spray (1 mg melatonin)
Study: 37438759
Drug: Swallowing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing and oral-care (SOC) program; average of 6.2 days of intervention (14.8 min daily).
Study: 37438759
Drug: Swallowing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing and oral-care (SOC) program; adjusted hazard ratio 2.35; 95% CI 1.38-4.01.
Study: 37438759
Drug: Swallowing and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Swallowing and oral-care (SOC) program; adjusted odds ratio 0.28; 95% CI 0.12-0.65.
Study: 37438776
Drug: Nudge intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nudge intervention comprising three SMS text message reminders with links to short educational videos and vaccine safety information.
Study: 37439084
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy with radiotherapy (n=18)
Study: 37439084
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy without radiotherapy (n=5)
Study: 37439219
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase followed by coronary angiography and PCI (if indicated)
Study: 37439219
Drug: Half-dose tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Half-dose tenecteplase and Primary PCI
Study: 37439343
Drug: Tenalisib 800
Normalized name: Tenalisib
DrugBank: Tenalisib (DB15295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenalisib 800 mg twice daily orally and romidepsin 14 mg/m2 intravenous on days 1, 8, and 15 in 28-day cycles
Study: 37439373
Drug: Metabolite levels
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Metabolite levels (S1P, L-arginine, kynurenine, acyl-carnitines, bile acids)
Study: 37439451
Drug: Exercise prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescriptions by physiotherapists for case one
Study: 37439451
Drug: Exercise prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescriptions by physiotherapists for case two
Study: 37439451
Drug: Exercise prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise prescriptions by physiotherapists for case three
Study: 37439701
Drug: Heterologous SCB-2019
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heterologous SCB-2019 booster (full or half dose)
Study: 37439701
Drug: Full-dose SCB-2019
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose SCB-2019 booster
Study: 37439701
Drug: Half-dose SCB-2019
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Half-dose SCB-2019 booster
Study: 37439701
Drug: SCB-2019 booster
Normalized name: SCB-2019
DrugBank: SCB-2019 (DB15805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCB-2019 booster (full or half dose)
Study: 37440217
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg/d for those with body weight <77 kg and/or platelet count <150 ×103/μL; 300 mg/d otherwise)
Study: 37440232
Drug: Internet-delivered emotion
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internet-delivered emotion regulation therapy plus treatment as usual
Study: 37440230
Drug: Friendship Bench
Normalized name: beach strawberry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Friendship Bench intervention (6 lay health worker-led weekly problem-solving therapy sessions)
Study: 37440239
Drug: Metronomic oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic oral vinorelbine, cyclophosphamide, and capecitabine (VEX)
Study: 37440239
Drug: Weekly intravenous
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intravenous paclitaxel
Study: 37441145
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) treatment using pressure pain threshold strong response acupoints (PSA) and temperature strong response acupoints (TSA)
Study: 37441145
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) treatment using clinical common acupoint (CCA)
Study: 37441145
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) treatment using TSA
Study: 37441145
Drug: Intradermal acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal acupuncture (IA) treatment using PSA
Study: 37441479
Drug: Iptacopan (LNP023),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iptacopan (LNP023), an oral, first-in-class, highly potent, proximal alternative pathway inhibitor.
Study: 37441500
Drug: 10 L
Normalized name: PEG-10 LANOLIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 L of oxygen per minute in a tight-fitting simple facemask until delivery
Study: 37441544
Drug: Observation after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation after local treatment
Study: 37441546
Drug: Preventive treatment
Normalized name: STANNOUS FLUORIDE 0.004 g in 1 g DENTAL GEL [Enamelon Preventive Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preventive treatment according to investigator preference (Arm B)
Study: 37442152
Drug: JNJ-3989 dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JNJ-3989 dual 40 mg group
Study: 37442152
Drug: JNJ-3989 dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JNJ-3989 dual 100 mg group
Study: 37442152
Drug: JNJ-3989 dual
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: JNJ-3989 dual 200 mg group
Study: 37442152
Drug: Triple group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple group (JNJ-6379 250 mg plus JNJ-3989 100 mg plus nucleos(t)ide analogues)
Study: 37442656
Drug: Dapagliflozin/metformin extended
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/metformin extended release (XR) (5/500 mg)
Study: 37442656
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg) and metformin XR (1000 mg)
Study: 37442656
Drug: Dapagliflozin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin/metformin FDC
Study: 37442656
Drug: IC tablets
Normalized name: Nature's Way Turmeric Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC tablets (dapagliflozin [5 mg] and metformin XR [500 mg])
Study: 37442748
Drug: Sugemalimab 1200
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab 1200 mg every 3 weeks for up to 12 months
Study: 37442748
Drug: Sugemalimab 1200
Normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugemalimab 1200 mg
Study: 37442883
Drug: Oral Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral Misoprostol (25μg every 4 hours, maximum 5 doses)
Study: 37442883
Drug: Oxytocin infusion
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin infusion (according to hospital protocol)
Study: 37443083
Drug: Intravenous Ringer's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Ringer's Lactate (RL)
Study: 37443452
Drug: SCH-TPOAb [-]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCH-TPOAb [-] group (levothyroxine treatment)
Study: 37443809
Drug: Increased CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased CRP protein levels of ≥5 mg/L
Study: 37444406
Drug: Current MDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current MDS treatments
Study: 37444551
Drug: Sorafenib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib (400 mg, po BID)
Study: 37444551
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of Sorafenib treatment
Study: 37444551
Drug: Maintenance of
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance of Sorafenib treatment
Study: 37444634
Drug: High-dose radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose radiation treatment for brain regions with Cho/NAA ≥ 2x normal
Study: 37446173
Drug: Nitisinone treatment
Normalized name: Nitisinone
DrugBank: Nitisinone (DB00348)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Nitisinone treatment
Study: 37448202
Drug: Nutrition +
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition + exercise intervention (bi-weekly nutrition counselling, high dairy protein diet, walking goal of 10,000 steps/day, plus usual prenatal care)
Study: 37448353
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (1.0 to 1.5 g orally)
Study: 37448694
Drug: Hydroxychloroquine 300
Normalized name: hydroxychloroquine 300 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxychloroquine 300 mg daily for six months
Study: 37449567
Drug: 30 months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 months of Dual Antiplatelet Therapy (DAPT)
Study: 37449567
Drug: 12 months
Normalized name: Elecare HMO 0-12 Months
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 months of Dual Antiplatelet Therapy (DAPT)
Study: 37449658
Drug: Denosumab (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denosumab (120 mg subcutaneously on day 1 of every 4-week cycle, with loading doses of 120 mg on days 8 and 15)
Study: 37449715
Drug: Younger survivors,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Younger survivors, gynecological cancer survivors, or those who received external and internal radiation or additional chemotherapy
Study: 37449716
Drug: sacubitril/valsartan (97/103
Approvals — FDA: no, EMA: no, PMDA: no
Description: sacubitril/valsartan (97/103 mg twice daily)
Study: 37449768
Drug: EMM +
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: EMM + $1 per day for perfect medication adherence for 3 months (maximum $84) followed by 1 month of EMM only
Study: 37449908
Drug: SEL-212 (ImmTOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: SEL-212 (ImmTOR 0.15 mg/kg and pegadricase 0.2 mg/kg)
Study: 37449908
Drug: Pegloticase (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pegloticase (8 mg)
Study: 37450196
Drug: Fast-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast-acting insulin aspart (faster aspart)
Study: 37450351
Drug: Endocrine Therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine Therapy (ET) + SMAC mimetics
Study: 37450613
Drug: Retrospective analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Retrospective analysis of troponin <5 ng/L
Study: 37450935
Drug: Long-term Doxycycline
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term Doxycycline therapy
Study: 37451291
Drug: Pembrolizumab 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 400 mg intravenously every 6 weeks for up to 18 cycles (2 years) plus lenvatinib 20 mg orally once daily.
Study: 37451295
Drug: Nivolumab 480
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 480 mg every 4 weeks for 1 year
Study: 37451297
Drug: Oral lenacapavir
Normalized name: Lenacapavir
DrugBank: Lenacapavir (DB15673)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral lenacapavir (600 mg, days 1 and 2; 300 mg, day 8) followed by subcutaneous lenacapavir 927 mg every 26 weeks
Study: 37451297
Drug: Optimised background
Normalized name: Optimised human arginase I
DrugBank: Pegzilarginase (DB14780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimised background regimen concurrent with lenacapavir (oral to subcutaneous)
Study: 37451297
Drug: Placebo followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo followed by lenacapavir (2-week oral lead-in then subcutaneous)
Study: 37451701
Drug: Bisoprolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (maximum 5 mg)
Study: 37451701
Drug: Celiprolol (maximum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (maximum 400 mg)
Study: 37451727
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy program (MTP) consisting of four sessions (once per week) of manual therapy applied to temporomandibular structures.
Study: 37451735
Drug: Vitamin K2
Normalized name: Vitamin K2
DrugBank: Menaquinone 6 (DB14936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K2 (720 µg/day) and vitamin D3 (25 µg/day) for 2 years
Study: 37451735
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (no active treatment) for 2 years
Study: 37451740
Drug: Prehabilitation intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prehabilitation intervention (4 weeks, 1 weekly session of ~1 to 1.5 hours)
Study: 37451877
Drug: Flumos-v1 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumos-v1 vaccine (tetravalent mosaic influenza nanoparticle vaccine)
Study: 37452107
Drug: Adjuvant immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immune checkpoint inhibitors (ICIs) alone
Study: 37452107
Drug: Adjuvant immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immune checkpoint inhibitors (ICIs) with tyrosine kinase inhibitors (TKIs)
Study: 37452107
Drug: Adjuvant therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant therapy (either ICIs alone or with TKIs)
Study: 37452107
Drug: Adjuvant immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant immune checkpoint inhibitors (ICIs) alone or with TKIs
Study: 37452281
Drug: TaU +
Normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TaU + MIND (mindfulness-based intervention added to treatment as usual)
Study: 37452330
Drug: Topical ketorolac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ketorolac tromethamine 0.5% three times a day
Study: 37452356
Drug: Unity prosthetic
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unity prosthetic add-on suspension system
Study: 37452707
Drug: Anakinra (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra (100 mg subcutaneous within 8 hours of onset, followed by five 100 mg subcutaneous injections every 12 hours)
Study: 37452707
Drug: Placebo (matched
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matched to anakinra treatment)
Study: 37453361
Drug: Third vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Third vaccine dose
Study: 37453361
Drug: Fourth vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fourth vaccine dose
Study: 37453361
Drug: Three doses
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three doses and infection
Study: 37453361
Drug: Three and
Normalized name: ZINC OXIDE 150 mg in 1 mL TOPICAL CREAM [Slip Tint Broad Spectrum SPF 35 Sunscreen Tinted Moisturizer Shade Three and Half]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three and four vaccine doses
Study: 37453361
Drug: Specific primary
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific primary immunodeficiencies and immunosuppressive medication
Study: 37454014
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of preoperative endocrine therapy (pre-ET)
Study: 37454537
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid with panitumumab (Pmab) as maintenance therapy
Study: 37454537
Drug: Fluorouracil and
Normalized name: Fluorouracil and salicylic acid only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluorouracil and folinic acid without panitumumab (Pmab) as maintenance therapy
Study: 37454762
Drug: High flow
Normalized name: Blood Set High Flow
Approvals — FDA: no, EMA: no, PMDA: no
Description: High flow oxygen (HFO) > 6 l/minute
Study: 37454789
Drug: 5% potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% potassium nitrate solution (control)
Study: 37455237
Drug: 14-day AZLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day AZLI (75 mg three times daily for 14 days)
Study: 37455237
Drug: 28-day AZLI
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28-day AZLI (75 mg three times daily for 28 days)
Study: 37455404
Drug: Diazepam nasal
Normalized name: diazepam Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam nasal spray (Valtoco) as rescue therapy for seizure clusters
Study: 37455496
Drug: Ramucirumab (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab (8 mg/kg i.v. on day 1 and 15, Q2W) plus TAS-102 (35 mg/m²)
Study: 37455588
Drug: Ritlecitinib 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 30 mg and higher
Study: 37456358
Drug: Carrying genetic
Normalized name: Burosumab (genetical recombination)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carrying genetic variants of OPRM1 (rs1799971, A>G)
Study: 37456507
Drug: Risedronate (bisphosphonate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate (bisphosphonate), administered monthly for six months
Study: 37456802
Drug: Dermocosmetic (DC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dermocosmetic (DC) applied twice a day for 28 days
Study: 37456813
Drug: Written exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Written exercise prescription (control group)
Study: 37457622
Drug: Colchicine (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine (0.5 mg tablet) given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Study: 37457622
Drug: Placebo, given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, given twice daily starting 2 to 4 hours before surgery for a total of 10 days
Study: 37458583
Drug: TDF+pegIFN+NAPs (early
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF+pegIFN+NAPs (early triple therapy group)
Study: 37458583
Drug: TDF+pegIFN (delayed
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF+pegIFN (delayed triple therapy group)
Study: 37459086
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral challenge with penicillin
Study: 37459086
Drug: Standard-of-care: penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care: penicillin skin testing followed by oral challenge
Study: 37459153
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous magnesium sulfate (IVMg)
Study: 37459153
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous magnesium sulfate (IVMg)
Study: 37459248
Drug: Obexelimab 5
Normalized name: Obexelimab
DrugBank: Obexelimab (DB15032)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Obexelimab 5 mg/kg intravenously every 2 weeks until week 32 or loss of improvement (LOI)
Study: 37460214
Drug: Absence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absence of bridging intravenous thrombolysis
Study: 37460276
Drug: Nebulised nezulcitinib
Normalized name: NEZULCITINIB
DrugBank: TD-0903 (DB16463)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised nezulcitinib 3 mg
Study: 37460603
Drug: Minzasolmin (UCB0599)
Normalized name: Minzasolmin
DrugBank: Minzasolmin (DB18961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minzasolmin (UCB0599) administered at doses of 1 and 5 mg/kg intraperitoneally for three months.
Study: 37460683
Drug: Short-term neoadjuvant
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term neoadjuvant endocrine therapy (NET) for 4 weeks (± 1 week)
Study: 37461024
Drug: Low load
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low load blood flow restriction (LL-BFR) delivered twice daily at 20% 1-RM
Study: 37461034
Drug: XLJDOD compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: XLJDOD compound granule
Study: 37461458
Drug: Comunică intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comunică intervention (motivational interviewing and cognitive-behavioral therapy skills across eight live text-based counseling sessions)
Study: 37461954
Drug: ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozanimod 0.92 mg
Study: 37461956
Drug: Ozanimod 0.92
Normalized name: ozanimod 0.92 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ozanimod 0.92 mg once daily